Search Results - "Childs, BH"

Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma by Dreyling, M., Morschhauser, F., Bouabdallah, K., Bron, D., Cunningham, D., Assouline, S.E., Verhoef, G., Linton, K., Thieblemont, C., Vitolo, U., Hiemeyer, F., Giurescu, M., Garcia-Vargas, J., Gorbatchevsky, I., Liu, L., Koechert, K., Peña, C., Neves, M., Childs, B.H., Zinzani, P.L.

“…Copanlisib is a pan-class I phosphatidylinositol 3-kinase inhibitor with predominant activity against the α- and δ-isoforms. This phase II study evaluated the…”
Get full text

Adoptive Immunotherapy Evaluating Escalating Doses of Donor Leukocytes for Relapse of Chronic Myeloid Leukemia After Bone Marrow Transplantation: Separation of Graft-Versus-Leukemia Responses From Graft-Versus-Host Disease by Mackinnon, Stephen, Papadopoulos, Esperanza B., Carabasi, Matthew H., Reich, Lilian, Collins, Nancy H., Boulad, Farid, Castro-Malaspina, Hugo, Childs, Barrett H., Gillio, Alfred P., Kernan, Nancy A., Small, Trudy N., Young, James W., O'Reilly, Richard J.

“…Infusions of large numbers (>108/kg) of donor leukocytes can induce remissions in patients with chronic myeloid leukemia (CML) who relapse after marrow…”
Get full text

Abstract P3-04-15: The PI3K-inhibitor, copanlisib, has selective activity in luminal breast cancer cell lines and shows robust combined activity with hormonal blockade and CDK-4/6 inhibition in ER+ breast cancer cell line xenografts by O'Brien, NA, Conklin, D, Luo, T, Ayala, R, Issakhanian, S, Kalous, O, Von Euw, E, Politz, O, Wilhelm, S, Childs, BH, Hurvitz, SA, Slamon, DJ

“…Abstract Background: Genetic and epigenetic alterations in the PI3K/mTOR and cyclin D:CDK-4/6:Rb signaling axes occur frequently in breast cancer and have been…”
Get full text

Comparison of Immune Reconstitution After Unrelated and Related T-Cell–Depleted Bone Marrow Transplantation: Effect of Patient Age and Donor Leukocyte Infusions by Small, T.N., Papadopoulos, E.B., Boulad, F., Black, P., Castro-Malaspina, H., Childs, B.H., Collins, N., Gillio, A., George, D., Jakubowski, A., Heller, G., Fazzari, M., Kernan, N., MacKinnon, S., Szabolcs, P., Young, J.W., O’Reilly, R.J.

“…Unrelated bone marrow transplantation (BMT) is often complicated by fatal opportunistic infections. To evaluate features unique to immune reconstitution after…”
Get full text

Abstract P6-12-08: Phase II Multicenter Study of Docetaxel and Bevacizumab (Bev) +/− Trastuzumab as First-Line Treatment of Patients with Metastatic Breast Cancer (MBC) by Schwartzberg, LS, Hermann, R, Blakely, J, Richey, SS, Tauer, KW, Childs, BH

“…Abstract Background: The addition of Bev to the taxanes docetaxel and paclitaxel has resulted in improved progression-free survival (PFS) in the first line…”
Get full text

CLINICAL OUTCOMES AND MOLECULAR CHARACTERIZATION FROM a PHASE II STUDY OF COPANLISIB IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA by Lenz, G., Hawkes, E., Verhoef, G., Haioun, C., Lim, S., Heo, D., Ardeshna, K., Chong, G., Christensen, J.H., Shi, V., Lippert, S., Hiemeyer, F., Piraino, P., Beckmann, G., Peña, C., Buvaylo, V., Childs, B.H., Gorbatchevsky, I., Salles, G.

Get full text

COPANLISIB IN PATIENTS WITH RELAPSED OR REFRACTORY INDOLENT B‐CELL LYMPHOMA (CHRONOS‐1) by Dreyling, M., Santoro, A., Mollica, L., Leppä, S., Follows, G.A., Lenz, G., Kim, W., Nagler, A., Panayiotidis, P., Demeter, J., Özcan, M., Kosinova, M., Bouabdallah, K., Morschhauser, F., Stevens, D.A., Trevarthen, D., Giurescu, M., Liu, L., Koechert, K., Peña, C., Cupit, L., Yin, S., Hiemeyer, F., Garcia‐Vargas, J., Childs, B.H., Zinzani, P.

Get full text

Infusions of Donor Leukocytes to Treat Epstein-Barr Virus-Associated Lymphoproliferative Disorders after Allogeneic Bone Marrow Transplantation by Papadopoulos, Esperanza B, Ladanyi, Marc, Emanuel, David, Mackinnon, Stephen, Boulad, Farid, Carabasi, Matthew H, Castro-Malaspina, Hugo, Childs, Barrett H, Gillio, Alfred P, Small, Trudy N, Young, James W, Kernan, Nancy A, O'Reilly, Richard J

“…In marrow-transplant recipients, lymphoproliferative disorders associated with Epstein-Barr virus (EBV) usually present as malignant B-cell lymphomas of donor…”
Get full text

Preliminary safety results: addition of bevacizumab to 3 docetaxel regimens as adjuvant therapy for early stage breast cancer by Yardley, DA, Hart, L, Waterhouse, DM, Badarinath, S, Daniel, B, Cook, D, Thompson, J, Childs, BH, Burris, HA

“…Abstract Abstract #4107 Background: Docetaxel-containing chemotherapy regimens improve disease-free survival (DFS) and overall survival in early stage breast…”
Get full text

Antileukemia activity of a natural killer cell line against human leukemias by YING YAN, STEINHERZ, P, KLINGEMANN, H.-G, DENNIG, D, CHILDS, B. H, MCGUIRK, J, O'REILLY, R. J

“…We describe here the in vitro and in vivo antileukemia activity of a recently described natural killer (NK) cell line (NK-92), which has features of human…”
Get full text

T-Cell–Depleted Allogeneic Bone Marrow Transplantation as Postremission Therapy for Acute Myelogenous Leukemia: Freedom From Relapse in the Absence of Graft-Versus-Host Disease by Papadopoulos, Esperanza B., Carabasi, Matthew H., Castro-Malaspina, Hugo, Childs, Barrett H., Mackinnon, Stephen, Boulad, Farid, Gillio, Alfred P., Kernan, Nancy A., Small, Trudy N., Szabolcs, Paul, Taylor, Joanne, Yahalom, Joachim, Collins, Nancy H., Bleau, Sharon A., Black, Patricia M., Heller, Glenn, Reilly, Richard J. O', Young, James W.

“…Thirty-one consecutive patients with acute myelogenous leukemia (AML) in first complete remission and 8 with AML in second complete remission received T…”
Get full text

INTEGRATED SAFETY DATA WITH COPANLISIB MONOTHERAPY FROM PHASE I AND II TRIALS IN PATIENTS WITH RELAPSED INDOLENT NON‐HODGKIN'S LYMPHOMA by Zinzani, P., Dreyling, M., Patnaik, A., Morschhauser, F., Benson, A., Genvresse, I., Miriyala, A., Garcia‐Vargas, J., Childs, B.H.

Get full text

GRB7 -dependent pathways are potential therapeutic targets in triple-negative breast cancer by Sparano, JA, Gray, R, Goldstein, LJ, Childs, BH, Bugarini, R, Rowley, S, Baker, J, Shak, S, Badve, S, Baehner, FL, Perez, EA, Shulman, LN, Martino, S, Sledge Jr, GW, Davidson, NE

“…Abstract Abstract #25 Background: Breast cancer lacking expression of the estrogen and progesterone receptor and overexpression of HER2/neu (ie,…”
Get full text

High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma: long-term follow-up by Abrey, Lauren E, Childs, Barrett H, Paleologos, Nina, Kaminer, Lynne, Rosenfeld, Steven, Salzman, Donna, Finlay, Jonathan L, Gardner, Sharon, Peterson, Kendra, Hu, Wendy, Swinnen, Lode, Bayer, Robert, Forsyth, Peter, Stewart, Douglas, Smith, Anne M, Macdonald, David R, Weaver, Susan, Ramsay, David A, Nimer, Stephen D, DeAngelis, Lisa M, Cairncross, J Gregory

“…We previously reported a phase 2 trial of 69 patients with newly diagnosed anaplastic or aggressive oligodendroglioma who were treated with intensive…”
Get full text

SAFETY RUN‐IN OF COPANLISIB IN COMBINATION WITH RITUXIMAB PLUS BENDAMUSTINE IN PATIENTS WITH RELAPSED INDOLENT NON‐HODGKIN'S LYMPHOMA by Gerecitano, J., Santoro, A., Leppä, S., Kim, T., Kim, W., Janssens, A., Pedersen, M., Reis, D., Granvil, C., Shen, J., Zheng, H., Childs, B.H., Zinzani, P.

Get full text

RIP kinase is involved in arsenic-induced apoptosis in multiple myeloma cells by Bajenova, O, Tang, B, Pearse, R, Feinman, R, Childs, B H, Michaeli, J

“…These studies explore the molecular effect of arsenicals on MM cells. Freshly isolated cells derived from patients with advanced, chemo-refractory myeloma as…”
Get full text

Dynamics of hematopoiesis in paroxysmal nocturnal hemoglobinuria (PNH): no evidence for intrinsic growth advantage of PNH clones by ARATEN, D. J, BESSLER, M, MCKENZIE, S, CASTRO-MALASPINA, H, CHILDS, B. H, BOULAD, F, KARADIMITRIS, A, NOTARO, R, LUZZATTO, L

“…PNH is characterized by expansion of one or more stem cell clones with a PIG-A mutation, which causes a severe deficiency in the expression of…”
Get full text

Cytogenetic and morphological abnormalities in paroxysmal nocturnal haemoglobinuria by Araten, David J., Swirsky, David, Karadimitris, Anastasios, Notaro, Rosario, Nafa, Khedoudja, Bessler, Monica, Thaler, Howard T., Castro‐Malaspina, Hugo, Childs, Barrett H., Boulad, Farid, Weiss, Mark, Anagnostopoulos, Nikolaos, Kutlar, Abdullah, Savage, David G., Maziarz, Richard T., Jhanwar, Suresh, Luzzatto, Lucio

“…Paroxysmal nocturnal haemoglobinuria (PNH) is characterized by the expansion of a haematopoietic stem cell clone with a PIG‐A mutation (the PNH clone) in an…”
Get full text

High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma by ABREY, Lauren E, CHILDS, Barrett H, SWINNEN, Lode, BAYER, Robert, FORSYTH, Peter, STEWART, Douglas, SMITH, Anne M, MACDONALD, David R, WEAVER, Susan, RAMSEY, David A, NIMER, Stephen D, DEANGELIS, Lisa M, PALEOLOGOS, Nina, CAIRNCROSS, J. Gregory, KAMINER, Lynne, ROSENFELD, Steven, SALZMAN, Donna, FINLAY, Jonathan L, GARDNER, Sharon, PETERSON, Kendra, HU, Wendy

“…Anaplastic oligodendroglioma is a chemosensitive glial neoplasm. To improve disease control and postpone cranial radiotherapy, we designed a phase II study of…”
Get full text

High dose chemotherapy with autologous stem cell rescue in adults with malignant primary brain tumors by ABREY, L. E, ROSENBLUM, M. K, PAPADOPOULOS, E, CHILDS, B. H, FINLAY, J. L

“…High dose chemotherapy (HDCT) with autologous (bone marrow or peripheral blood) stem cell rescue (ASCR) has had success in the treatment of some malignant…”
Get full text